{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+capsule&page=16", "query": { "intervention": "Active capsule", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 1413, "total_pages": 142, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+capsule&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+capsule&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T00:46:52.870Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02092935", "title": "A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clostridium Difficile Infection" ], "interventions": [ { "name": "SMT19969", "type": "DRUG" }, { "name": "Vancomycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Summit Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 100, "start_date": "2014-04", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2016-10-20", "last_synced_at": "2026-10-24T00:46:52.870Z", "location_count": 24, "location_summary": "Mobile, Alabama • Laguna Hills, California • Long Beach, California + 21 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Laguna Hills", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Sylmar", "state": "California" }, { "city": "Ventura", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02092935" }, { "nct_id": "NCT04451772", "title": "A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Lupus Erythematosus (SLE)" ], "interventions": [ { "name": "Elsubrutinib", "type": "DRUG" }, { "name": "Placebo for Elsubrutinib", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Placebo for Upadacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 185, "start_date": "2020-07-27", "completion_date": "2024-01-03", "has_results": true, "last_update_posted_date": "2025-01-14", "last_synced_at": "2026-10-24T00:46:52.870Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Los Alamitos, California + 18 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "San Leandro", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04451772" }, { "nct_id": "NCT01677195", "title": "Phase 2 Reduction of Dietary Mycotoxin Exposure by ACCS100\"", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dietary Carcinogenesis" ], "interventions": [ { "name": "ACCS100", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Texas Enterosorbents Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 234, "start_date": "2012-09", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2016-04-19", "last_synced_at": "2026-10-24T00:46:52.870Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01677195" }, { "nct_id": "NCT06720909", "title": "Mindfulness And Placebo for Pain (MAPP) Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Pain" ], "interventions": [ { "name": "Mindfulness-Based Stress Reduction (MBSR)", "type": "BEHAVIORAL" }, { "name": "Open-Label Placebo (OLP)", "type": "OTHER" }, { "name": "MBSR+OLP", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Arizona State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2025-01-27", "completion_date": "2027-03-01", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-10-24T00:46:52.870Z", "location_count": 2, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06720909" }, { "nct_id": "NCT04730193", "title": "Caffeine and Cerebrovascular Reactivity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Caffeine" ], "interventions": [ { "name": "Caffeine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "21 Years to 85 Years" }, "enrollment_count": 10, "start_date": "2021-02-01", "completion_date": "2022-08-01", "has_results": false, "last_update_posted_date": "2022-08-09", "last_synced_at": "2026-10-24T00:46:52.870Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT04730193" }, { "nct_id": "NCT00377637", "title": "A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lupus Nephritis" ], "interventions": [ { "name": "Mycophenolate mofetil (MMF)", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" }, { "name": "Placebo to Azathioprine", "type": "DRUG" }, { "name": "Placebo to Mycophenolate mofetil", "type": "DRUG" }, { "name": "Corticosteroid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 370, "start_date": "2005-07", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2011-12-06", "last_synced_at": "2026-10-24T00:46:52.870Z", "location_count": 28, "location_summary": "Huntsville, Alabama • La Jolla, California • Los Angeles, California + 22 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Leandro", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00377637" }, { "nct_id": "NCT07206901", "title": "Evaluation of an Ayurvedic Herbal Compound Compared to Vitamins C+E and Placebo on Vascular Function in High-Risk Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Coronary Artery Disease" ], "interventions": [ { "name": "Maharishi Amrit Kalash", "type": "DIETARY_SUPPLEMENT" }, { "name": "vitamin C + E", "type": "DIETARY_SUPPLEMENT" }, { "name": "Inert Placebo Capsule", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "Maharishi International University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "55 Years to 90 Years" }, "enrollment_count": 143, "start_date": "2002-10-14", "completion_date": "2014-10-27", "has_results": false, "last_update_posted_date": "2025-10-03", "last_synced_at": "2026-10-24T00:46:52.870Z", "location_count": 1, "location_summary": "Fairfield, Iowa", "locations": [ { "city": "Fairfield", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT07206901" }, { "nct_id": "NCT02730481", "title": "A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Oraxol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Athenex, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2016-03", "completion_date": "2021-05", "has_results": false, "last_update_posted_date": "2021-09-13", "last_synced_at": "2026-10-24T00:46:52.870Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Buffalo, New York • San Antonio, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Buffalo", "state": "New York" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02730481" }, { "nct_id": "NCT05006430", "title": "Safety Evaluation of Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Alcoholic Hepatitis" ], "interventions": [ { "name": "Fecal Microbiota Transplantation", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Prasun Kumar Jalal", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 50, "start_date": "2023-01-21", "completion_date": "2025-06-30", "has_results": false, "last_update_posted_date": "2025-01-23", "last_synced_at": "2026-10-24T00:46:52.870Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05006430" }, { "nct_id": "NCT03934099", "title": "A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gout", "Hyperuricemia" ], "interventions": [ { "name": "LC350189 formulated capsule", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "LG Chem", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 156, "start_date": "2019-12-02", "completion_date": "2021-05-17", "has_results": true, "last_update_posted_date": "2025-12-03", "last_synced_at": "2026-10-24T00:46:52.870Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03934099" } ] }